Known targets — ChEMBL curated mechanism
COXFA4COXFA4L2GPD2MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3
The experimentally established mechanism targets of Metformin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metformin SCHEMBL15268394 | 1.00 | HTT (0.39) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL22977 | 1.00 | HTT (0.39) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL18953625 | 1.00 | HTT (0.39) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL19583451 | 1.00 | HTT (0.39) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL1547913 | 1.00 | HTT (0.39) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL4421557 | 1.00 | HTT (0.39) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL28854120 | 0.97 | HTT (0.37) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL1714633 | 0.97 | HTT (0.37) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL1747396 | 0.97 | HTT (0.37) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL4200501 | 0.97 | HTT (0.37) | HTTLMNADPP4ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595637-B1 | REGULATORY IMMUNE CELLS WITH ENHANCED TARGETED CELL DEATH EFFECT | CELLECT BIOTHERAPEUTICS LTD (IL) | 2017-11-01 | — | — | EP | disclosed |
| US-9624469-B2 | Regulatory immune cells with enhanced targeted cell death effect | CELLECT BIOTHERAPEUTICS LTD. (IL) | 2017-04-18 | — | — | US | disclosed |
| EP-3075396-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INSULIN-ASSOCIATED MEDICAL CONDITIONS | Yeda Research and Development Co. Ltd. (IL) | 2016-10-05 | — | — | EP | disclosed |
| US-9382187-B2 | Tri-salt form of metformin | THETIS PHARMACEUTICALS LLC (US) | 2016-07-05 | — | — | US | disclosed |
| EP-2627766-B1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INSULIN-ASSOCIATED MEDICAL CONDITIONS | YEDA RES & DEV (IL) | 2016-05-25 | — | — | EP | disclosed |
| US-9301981-B2 | Methods and compositions for the treatment of insulin-associated medical conditions | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-04-05 | — | — | US | disclosed |
| US-20150197475-A1 | Tri-Salt Form of Metformin | CONNECTICUT INNOVATIONS, INC., AS COLLATERAL AGENT | 2015-07-16 | — | — | US | disclosed |
| EP-2892518-A2 | NEW THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE | Pharnext (FR) | 2015-07-15 | — | — | EP | disclosed |
| US-20150125433-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INSULIN-ASSOCIATED MEDICAL CONDITIONS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-05-07 | — | — | US | disclosed |
| US-8951983-B2 | Methods and compositions for the treatment of insulin-associated medical conditions | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-02-10 | — | — | US | disclosed |
| US-20080096915-A1 | An oral formulation of cicletanine and ruboxistaurin; diabetes, diabetic complications, dyslipidemia, and metabolic disorders | Greenberg Traurig LLP (US) | 2008-04-24 | — | — | US | disclosed |
| US-20070141174-A1 | Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension | NAVITAS PHARMA, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1608685-B1 | VEGF ANTAGONISTS FOR THE TREATMENT OF DIABETES | REGENERON PHARMA (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060089374-A1 | Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease | NAVITAS ASSETS, LLC | 2006-04-27 | — | — | US | disclosed |
| EP-1608685-A2 | METHODS OF TREATING DIABETES BY BLOCKING VEGF-MEDIATED ACTIVITY | REGENERON PHARMACEUTICALS, INC. (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050096264-A1 | Methods for treating obesity and related conditions with glycoprotein hormone beta family hormones | REGENERON PHARMACEUTICALS, INC. | 2005-05-05 | — | — | US | disclosed |
| US-6866866-B1 | Controlled release metformin compositions | ANDRX LABS, LLC (US) | 2005-03-15 | — | — | US | disclosed |
| US-20040213787-A1 | Methods of treating diabetes by blocking VEGF-mediated activity | REGENERON PHARMACEUTICALS, INC. | 2004-10-28 | — | — | US | disclosed |
| WO-2004087206-A2 | METHODS OF TREATING DIABETES BY BLOCKING VEGF-MEDIATED ACTIVITY | REGENERON PHARMACEUTICALS, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040157809-A1 | Composition comprising an androgen receptor blocker and an insulin sensitizing agent and use thereof for treatment of polycystic ovary syndrome | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197475-A1 | Tri-Salt Form of Metformin | TNNI3, FABP4, TNNT2 | HTT 1261/4885LMNA 3284/4885DPP4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.